Ohitinib-assisted treatment of early EGFR mutation lung cancer was recognized by the FDA as a breakthrough therapy.

On July 30, AstraZeneca announced that osimertinib(Tagrisso) had been identified in the United States as a therapeutic treatment for preoperative epidermal growth factor receptor mutation (EGFRM) non-small cell lung cancer (NSCLC) after complete excision.
the BTD determination is based on stunning results from the Clinical Phase 3 trial (ADAURA), whose Tagrisso reduces the risk of recurrence or death by about 80%.
Although up to 30% of non-small cell lung cancer patients can be diagnosed early and underlying curable surgery, recurrence of the disease is common in early stages of the disease; "Early EGFRm lung cancer patients often relapse even after successful surgery and complementary chemotherapy, but there is no approved targeted treatment to improve the prognosis," said Joss Baselga, executive vice president of astrazencya oncology research and development at

.
Tagrisso's Clinical Phase 3 trial (ADAURA) demonstrates its unprecedented level of clinical benefit in these patients, and we are working closely with the FDA to deliver this potential lying treatment to patients as soon as possible.
" breakthrough therapy is based on Clinical Phase 3 (ADAURA) data, which were recently presented at the American Society of Clinical Oncology's ASCO 2020 meeting.
ADAURA is a global, randomized, double-blind, placebo-controlled clinical Phase 3 trial in which 682 patients with IB, II, IIIA EGFRm NSCLC were enrolled in a group that had previously undergone complete excision and complementary chemotherapy.
in the trial group, patients received Tagrisso 80mg of daily oral tablet therapy for three years or until the disease returned.
in the trial, Tagrisso showed statistically significant and clinically significant improvements in disease-free survival (DFS) in assisted therapy in patients with IB-IIIA EGFRm NSCLC, reducing the risk of recurrence or death of the disease by 79% in key secondary endpoints (HR 0.21;95% CI 0.16-0.28; p-lt;0.0001).
April 2020, the Independent Data Monitoring Board recommended that the trial be debunked two years ahead of schedule, based on its overwhelming efficacy determination.
clinical results for the trial were initially expected to be available in 2022 and the trial will continue to evaluate OS.
osimertinib, Tagrisso is a third-generation, irreversible EGFR-TKI with clinical activity against CNS transfer.
40mg and 80mg of daily oral Tagrisso tablets have been approved for first-line treatment of locallate or metastatic EGFRm NSCLC patients in the United States, Japan, China, the European Union and many other countries around the world, as well as locallate or metastatic EGFR T790M mutation-positive NSCLC patients.
Tagrisso for Non-Removable Environments (LAURA), Neo-Assisted Excisecan Environment (NeoADAURA), Combined Chemotherapy (FLAURA2) and Joint Solution to EGFR-TKI Resistance (SAVANNAH, ORCHARD) with potential new drugs are also being developed in clinical phase 3.
References: s1 Tagrisso granted TheRapy In THE US for the adjuvant treatment of the patients with Stage IB-IIIA EGFR-mutated lung cancer. Retrieved 2020-07-30, from.